ACADIA Pharmaceuticals’ (ACAD) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) in a research report released on Thursday morning,Benzinga reports. The firm currently has a $28.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for ACADIA Pharmaceuticals’ FY2025 earnings at $0.15 EPS.

Other research analysts have also issued reports about the company. Guggenheim lowered ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $23.00 to $20.00 in a report on Friday, January 3rd. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday. StockNews.com lowered ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft began coverage on ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a “hold” rating and a $22.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday. Nine equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

ACADIA Pharmaceuticals Trading Up 1.3 %

ACAD stock opened at $19.60 on Thursday. The firm has a market capitalization of $3.26 billion, a PE ratio of 25.13 and a beta of 0.37. ACADIA Pharmaceuticals has a 1-year low of $14.15 and a 1-year high of $24.53. The business’s 50 day simple moving average is $18.42 and its 200 day simple moving average is $16.85.

Institutional Trading of ACADIA Pharmaceuticals

Several large investors have recently modified their holdings of ACAD. Creative Planning grew its holdings in shares of ACADIA Pharmaceuticals by 71.4% during the 3rd quarter. Creative Planning now owns 25,061 shares of the biopharmaceutical company’s stock worth $385,000 after purchasing an additional 10,441 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of ACADIA Pharmaceuticals by 11.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 121,625 shares of the biopharmaceutical company’s stock worth $1,871,000 after purchasing an additional 12,787 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of ACADIA Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,066 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of ACADIA Pharmaceuticals by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 31,903 shares of the biopharmaceutical company’s stock worth $491,000 after buying an additional 12,493 shares during the last quarter. Finally, US Bancorp DE lifted its position in shares of ACADIA Pharmaceuticals by 2,084.0% during the 3rd quarter. US Bancorp DE now owns 32,934 shares of the biopharmaceutical company’s stock worth $507,000 after buying an additional 31,426 shares during the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.